BFRG (Bullfrog AI Holdings Inc.) stock: $0.46, $8.6M market cap, $6.9M cash, $1.8M EV, $13.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$0.46
Market cap
$8.6M
Cash
$6.9M
Enterprise value
$1.8M
Balance sheet
Cash
$6.9M
Debt
$0.1M
Net cash
$6.8M
Enterprise value
$1.8M
Basic shares
18.5M shares
Fully diluted shares
28.6M shares
Fully diluted market cap
$13.1M
Cash per share
$0.37
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading BFRG daily closes…
Loading price history…
Pipeline assets
Beta2-spectrin siRNA
Preclinical · ActiveModality: siRNA
Target Beta2-spectrin
Partnerships George Washington University: exclusive worldwide license (Jan 2022); $20K initiation fee, 3% royalty + sublicense fees
Indications
Hepatocellular carcinoma(Preclinical)
Obesity / NAFLD / NASH(Preclinical)
Status note siRNA targeting Beta2-spectrin. Preclinical; company has not yet initiated development activities or IND-enabling studies (all R&D to date by licensor). BullFrog AI's core business is its bfLEAP AI/ML drug-development platform (fee-for-service); this is one of three in-licensed internal drug assets.
Status note Improved formulation of mebendazole evaluated in an investigator Phase 1 trial (NCT01729260) in newly diagnosed glioma with adjuvant temozolomide. Company is seeking a partner to conduct additional clinical trials.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.